|
 |
IT drives lifesciences
 |
|
| IT has made inroads into the hitherto closed lifesciences sector and now is making its presence felt. |
|
 |
|
|
| |
| Life Sciences Version 2.0
|
|
| Health Industry Insights (HII), an IDC company that provides market research and advisory services to health and life sciences industry, in January, released its series of top 10 predictions reports |
|
|
|
|
| |
| Stem cell research bushed out of USA
|
|
| The exodus of stem cell research from the US has started. Geron, based in Menlo Park, California, has become the first company to step up its stem cell research efforts in the UK. The company made this announcement on August 7 |
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| RNAi, the silent forerunner
|
|
| RNA interferencean innovation that quickly moved from discovery to a technology that enables drug discovery, drug development and therapeutic synthesis has big pharma in attention |
|
|
|
|
| |
| Acrux leveraging transdermal technology
|
|
| Australian drug delivery technology firm, Acrux is developing and commercializing a range of patient-preferred pharmaceutical products for global markets using an innovative, patented technology to administer drugs through the skin |
|
|
|
|
| |
| IVD market on fast track
|
|
| Fuelled by strong double-digit growth rates of segments such as molecular diagnostics and diabetes care the in vitro diagnostic segment is set to take off in a big way, with worldwide sales expected to surpass $44.5 billion by 2010 |
|
|
|
|
| More |
SITE MAP 
